1. Boardman AE, Greenberg DH, Vining AR, Weimer DL (2001) Cost-benefit analysis-concepts and practice, 2nd edn. Prentice Hall
2. Ellig J, Morrall J (2010) Assessing the quality of regulatory analysis: a new evaluation and data set for policy research
3. FDA (2004) Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final Rule US Federal Reg 69(28):6787–6854. https://pubmed.ncbi.nlm.nih.gov/15364637/
4. Fox J (2007) The uncertain relationship between transparency and accountability. Development in Practice, Taylor & Francis
5. Fraas A, Lutter R (2011) Can greater use of economic analysis improve regulatory policy at independent regulatory commissions?. http://www.rff.org/events/pages/can-greater-use-of-economic-analysis-improve-regulatory-policy-at-independent-regulatory-agencies.aspx